These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 29561706)

  • 21. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
    Roberts AW; Huang D
    Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax for the treatment of chronic lymphocytic leukemia.
    Gentile M; Petrungaro A; Uccello G; Vigna E; Recchia AG; Caruso N; Bossio S; De Stefano L; Palummo A; Storino F; Martino M; Morabito F
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1307-1316. PubMed ID: 28972395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
    Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
    N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
    Salem AH; Agarwal SK; Dunbar M; Enschede SL; Humerickhouse RA; Wong SL
    J Clin Pharmacol; 2017 Apr; 57(4):484-492. PubMed ID: 27558232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax.
    Blombery P; Thompson ER; Nguyen T; Birkinshaw RW; Gong JN; Chen X; McBean M; Thijssen R; Conway T; Anderson MA; Seymour JF; Westerman DA; Czabotar PE; Huang DCS; Roberts AW
    Blood; 2020 Mar; 135(10):773-777. PubMed ID: 31951646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venetoclax: A new wave in hematooncology.
    Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
    Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
    Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
    Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
    Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
    [No Abstract]   [Full Text] [Related]  

  • 32. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions.
    Bennett R; Thompson E; Tam C
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):795-804. PubMed ID: 35970756
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
.
    Brumbaugh Paradis H; Alter D; Llerandi D
    Clin J Oncol Nurs; 2017 Oct; 21(5):604-610. PubMed ID: 28945711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A literature review of the patent publications on venetoclax - a selective Bcl-2 inhibitor: discovering the therapeutic potential of a novel chemotherapeutic agent.
    Žigart N; Časar Z
    Expert Opin Ther Pat; 2019 Jul; 29(7):487-496. PubMed ID: 31154862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathways and mechanisms of venetoclax resistance.
    Bose P; Gandhi V; Konopleva M
    Leuk Lymphoma; 2017 Sep; 58(9):1-17. PubMed ID: 28140720
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199.
    Bojarczuk K; Sasi BK; Gobessi S; Innocenti I; Pozzato G; Laurenti L; Efremov DG
    Blood; 2016 Jun; 127(25):3192-201. PubMed ID: 27095788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of BCL2 alternative proteins and association with outcome in CLL patients treated with venetoclax.
    Marques-Piubelli ML; Schlette EJ; Khoury JD; Furqan F; Vega F; Soto LMS; Wistuba II; Wierda WG; Konopleva M; Ferrajoli A; Strati P
    Leuk Lymphoma; 2021 May; 62(5):1129-1135. PubMed ID: 33327833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy.
    Liu J; Li S; Wang Q; Feng Y; Xing H; Yang X; Guo Y; Guo Y; Sun H; Liu X; Yang S; Mei Z; Zhu Y; Cheng Z; Chen S; Xu M; Zhang W; Wan N; Wang J; Ma Y; Zhang S; Luan X; Xu A; Li L; Wang H; Yang X; Hong Y; Xue H; Yuan X; Hu N; Song X; Wang Z; Liu X; Wang L; Liu Y
    Blood; 2024 May; 143(18):1825-1836. PubMed ID: 38211332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
    Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
    Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Venetoclax, the first BCL-2 inhibitor for use in patients with chronic lymphocytic leukemia.
    Seymour J
    Clin Adv Hematol Oncol; 2019 Aug; 17(8):440-443. PubMed ID: 31449511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.